00:14 – The Latest Updates About Tirzepatide and Semaglutide
01:35 – Insurance Companies and GLP-1 Coverage
02:30 – Navigating FDA Regulations: Is there still a shortage?
09:06 – Restoration of Supply
10:53 – Resolution of Manufacturing Issues
11:17 – Distribution Improvement
11:34 – No Anticipated Recurrence
12:08 – Reports from Manufacturers
12:31 – Healthcare Provider Feedback
13:02 – Severity of the Shortage
14:08 – Manufacturer Response
14:40 – Regulatory Compliance
15:06 – Supply Chain Stability
15:25 – FDA Evaluation
16:03 – Looking Ahead – Transitioning medications and new treatment options
20:56 – Research your next big thing NOW
25:04 – Sublingual Liraglutide Clinical Study
28:19 – How you’ll grow with us next
30:14 – Q&A
Stay informed with the latest updates on Tirzepatide and Semaglutide, two critical GLP-1 receptor agonists used for weight management and diabetes treatment. We’ll cover the ongoing drug shortages, potential resolutions from manufacturers, and how these issues impact patient care. Additionally, we’ll discuss changes in insurance coverage, particularly for banded medication, and explore new treatment options like sublingual liraglutide and NAD injections. Whether you’re a healthcare provider or patient, this video provides crucial insights to help navigate these developments.
#Tirzepatide #Semaglutide #DrugShortage #GLP1 #DiabetesTreatment #WeightLossMedication #CompoundingPharmacy #Liraglutide
